Crude Heparin Market Size Was valued at USD 9.1 Bn in 2024 and is predicted to reach USD 17.8 Bn by 2034 at a 7.2% CAGR during the forecast period for 2025-2034.
Crude heparin is an unprocessed, unrefined form of the anticoagulant medication heparin that is made from animal tissues, usually the lungs and intestines of cattle or pigs. It is a complex mixture of repeating sugar molecules called sulfated glycosaminoglycans. To eliminate contaminants and separate them into distinct fractions based on their molecular weight and activity, crude heparin is subjected to extraction and purification procedures. Since inadequate purification can result in contamination and negative effects, refining is essential to ensuring the safety and effectiveness of crude heparin. The growing incidence of venous thromboembolism (VTE) and other associated conditions is a major factor driving the crude heparin industry. Since the Centers for Disease Control and Prevention (CDC) estimates that 900,000 Americans suffer from VTE annually, there is a significant need for heparin and other effective anticoagulants.
Furthermore, the use of crude heparin to prevent thrombosis during and after surgeries has increased due to the growing number of surgical procedures performed worldwide. A further important aspect driving market expansion is the growing geriatric population. The demand for crude heparin is expected to increase due to the higher risk of cardiovascular diseases in older adults, presenting a significant market opportunity for those involved in its production and distribution.
However, the market for crude heparin is subject to several limitations that could hinder its growth, despite its encouraging development potential. One of the main concerns is the moral and legal dilemmas associated with the source of heparin. Concerns about sustainability and animal welfare are raised by the growing scrutiny of products derived from animals, which may lead to public opposition. Additionally, the market is susceptible to supply chain disruptions, as demonstrated during the COVID-19 pandemic, when acquiring raw materials proved challenging and impacted manufacturing schedules.
The crude heparin market is segmented based on source, application, formulation type, end-user, and distribution channel. Based on source, the market is segmented into porcine heparin Porcine Heparin (Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH)), and Bovine Heparin (Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH), Ultra-Low Molecular Weight Heparin (ULMWH)). By application, the market is segmented into surgical procedures, orthopedic, cardiovascular, and oncology. By formulation type, the market is segmented into injectable heparin and non-injectable formulations. By end-user, the market is segmented into hospitals, clinics, and long-term care facilities. By distribution channel the market is segmented into direct sales, pharmacies, online sales, and wholesalers.
The porcine heparin segment is expected to hold a major global market share in 2024 owing to the increased heparin output and purity obtained from pig intestines. The market for heparin from pigs has remained dominant because of its broad acceptability and long history of use in pharmaceutical applications. Well-established supply chains and manufacturing techniques facilitate this segment's sustained expansion. However, in other areas, religious prohibitions and animal welfare concerns have prompted research into alternative sources, such as bovine heparin.
On the other hand, bovine heparin, derived from cattle, is gaining popularity in areas where pig sources are restricted. Bovine heparin is a safe substitute for heparin obtained from pigs, and its return is largely due to improvements in purification technologies that ensure the elimination of any impurities. The increased availability of cattle in some areas, which offers a reasonably priced source of raw materials, is another factor driving the rising demand for bovine heparin.
One of the main end-user segments is hospitals, where heparin is widely utilized in clinical settings to treat and prevent blood clotting disorders. The high frequency of surgical procedures and the vital requirement for anticoagulant therapy in postoperative care are the reasons behind the hospital segment's dominance. The need for heparin in hospital settings is further fueled by the growing incidence of cardiovascular illnesses and the rise in hospital admissions for associated ailments.
The North American crude heparin market is expected to register the highest market share in revenue in the near future because of its robust pharmaceutical sector and sophisticated healthcare system. Due to the high incidence of cardiovascular disorders and the rising number of surgical procedures, the United States holds a significant market share. The presence of significant pharmaceutical firms and research facilities in North America contributes to the market's expansion by fostering innovation and the development of novel heparin-based treatments.
In addition, Asia Pacific is projected to grow rapidly in the global crude heparin market driven by the healthcare industry's explosive growth in nations like China and India, where rising healthcare costs and better healthcare infrastructure are commonplace. The Asia Pacific region is a desirable location for the manufacture and use of heparin due to the availability of affordable labor & raw materials, as well as encouraging government initiatives. The market's growth in this area is further aided by the increasing incidence of lifestyle-related illnesses and the increased knowledge of anticoagulant treatments.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 9.1 Bn |
|
Revenue Forecast In 2034 |
USD 17.8 Bn |
|
Growth Rate CAGR |
CAGR of 7.2% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Source, By Application, By Formulation Type, By End-User, By Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
DAT-Schaub, Suanfarma, Hepac (Darling Ingredients), Shenzhen Hepalink Pharmaceutical Group, Pharma Action (Tönnies Group), Aspen Oss, Bioiberica, Opocrin S.p.A., Celsus Laboratories, Fengrun Biological Technology, Nanjing King-friend Biochemical Pharmaceutical, Hebei Changshan Biochemical Pharmaceutical, Changzhou Qianhong Biopharma, Yantai Dongcheng Biochemicals, Huaian MDC Pharmaceutical, Qingdao Jiulong Biopharmaceutical, Shanghai Fosun Pharmaceutical, Sinopharm Chemical Reagent, Nantong Tianlong Animal By-products, Adeste, Syntex S.A., Laboratorios Heber, Instituto Bioclon, Bharat Biotech, Other Prominent Players. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Crude Heparin Market Snapshot
Chapter 4. Global Crude Heparin Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Crude Heparin Market Industry Trends
4.10. Global Crude Heparin Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Crude Heparin Market Segmentation 1: By Source of Crude Heparin, Estimates & Trend Analysis
5.1. Market Share by Source of Crude Heparin, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Source of Crude Heparin:
5.2.1. Porcine Heparin
5.2.1.1. Unfractionated Heparin (UFH)
5.2.1.2. Low Molecular Weight Heparin (LMWH)
5.2.1.3. Ultra-Low Molecular Weight Heparin (ULMWH)
5.2.2. Bovine Heparin
5.2.2.1. Unfractionated Heparin (UFH)
5.2.2.2. Low Molecular Weight Heparin (LMWH)
5.2.2.3. Ultra-Low Molecular Weight Heparin (ULMWH)
Chapter 6. Crude Heparin Market Segmentation 2: By Formulation Type, Estimates & Trend Analysis
6.1. Market Share by Formulation Type, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Formulation Type:
6.2.1. Injectable Heparin
6.2.2. Non-injectable Formulations
Chapter 7. Crude Heparin Market Segmentation 3: By End-User Industry, Estimates & Trend Analysis
7.1. Market Share by End-User Industry, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-User Industry:
7.2.1. Hospitals
7.2.2. Clinics
7.2.3. Long-term Care Facilities
Chapter 8. Offline Crude Heparin Market Segmentation 4: By Distribution Channel, Estimates & Trend Analysis
8.1. Market Share by Distribution Channel, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Distribution Channel:
8.2.1. Direct Sales
8.2.2. Online Sales
8.2.3. Pharmacies
8.2.4. Wholesalers
Chapter 9. Crude Heparin Market Segmentation 5: By Application, Estimates & Trend Analysis
9.1. Market Share by Application, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Application:
9.2.1. Surgical Procedures
9.2.2. Cardiovascular Applications
9.2.3. Orthopedic Applications
9.2.4. Oncology
Chapter 10. Crude Heparin Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Crude Heparin Market, Regional Snapshot 2024 & 2034
10.2. North America
10.2.1. North America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Source of Crude Heparin, 2021-2034
10.2.3. North America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Formulation Type, 2021-2034
10.2.4. North America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.2.5. North America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.2.6. North America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.3. Europe
10.3.1. Europe Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Source of Crude Heparin, 2021-2034
10.3.3. Europe Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Formulation Type, 2021-2034
10.3.4. Europe Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.3.5. Europe Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.3.6. Europe Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Source of Crude Heparin, 2021-2034
10.4.3. Asia Pacific Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Formulation Type, 2021-2034
10.4.4. Asia Pacific Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts Distribution Channel, 2021-2034
10.4.5. Asia Pacific Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.5. Latin America
10.5.1. Latin America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Source of Crude Heparin, 2021-2034
10.5.3. Latin America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Formulation Type, 2021-2034
10.5.4. Latin America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.5.5. Latin America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.5.6. Latin America Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Source of Crude Heparin, 2021-2034
10.6.3. Middle East & Africa Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Formulation Type, 2021-2034
10.6.4. Middle East & Africa Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by End-User Industry, 2021-2034
10.6.5. Middle East & Africa Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
10.6.6. Middle East & Africa Crude Heparin Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. DAT-Schaub
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Suanfarma
11.2.3. Hepac (Darling Ingredients)
11.2.4. Shenzhen Hepalink Pharmaceutical Group
11.2.5. Pharma Action (Tönnies Group)
11.2.6. Aspen Oss
11.2.7. Bioiberica
11.2.8. Opocrin S.p.A.
11.2.9. Celsus Laboratories
11.2.10. Fengrun Biological Technology
11.2.11. Nanjing King-friend Biochemical Pharmaceutical
11.2.12. Hebei Changshan Biochemical Pharmaceutical
11.2.13. Changzhou Qianhong Biopharma
11.2.14. Yantai Dongcheng Biochemicals
11.2.15. Huaian MDC Pharmaceutical
11.2.16. Qingdao Jiulong Biopharmaceutical
11.2.17. Shanghai Fosun Pharmaceutical
11.2.18. Sinopharm Chemical Reagent
11.2.19. Nantong Tianlong Animal By-products
11.2.20. Adeste
11.2.21. Syntex S.A.
11.2.22. Laboratorios Heber
11.2.23. Instituto Bioclon
11.2.24. Bharat Biotech
11.2.25. Other Prominent Players
Crude Heparin Market-By Source
Crude Heparin Market-By Application
Crude Heparin Market-By Formulation Type
Crude Heparin Market-By End-User
Crude Heparin Market-By Distribution Channel
Crude Heparin Market-By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
